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Modafinil (Provigil) belongs to a new pharmaceutical class known as eugeroics- 
translating to ‘good arousal’ agents. A distinct structure from classical psychostimulants, 
modafinil’s unique pharmacological property demonstrates wake-promoting and 
neuroprotective effects. This literature review presents a hypothesized mechanism of 
action, consolidates research of modafinil analogues and hybridizes a novel compound in 












Modafinil (±)-1 contains an asymmetric sulfoxide moiety, where modest 
enantioselectivity is observed between R-(-)- and S-(+)-modafinil. Investigations into the 
pharmacokinetic profile of armodafinil confirmed enantioselectivity at DAT for the R- 
and S-enantiomers was three-fold (Cao et al. 2011) and increased metabolic stability, 
eliminated three-times more slowly than the S-enantiomer (Robertson et al. 2003).  
Cephalon Inc. has marketed the racemic sulfoxide, Provigil, since approval in 1998 for 
R-(-)-modafinil	  S-(+)-modafinil	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narcolepsy. Expansion of its labeling from the initial indications, in 2004 modafinil was 
approved for treatment of excessive daytime sleepiness (EDS), obstructive sleep 
apnea/hypopnea syndrome (OSAHS) and shift-work sleep disorder (SWSD). With 
significance of these prescribing indications rapidly being eroded, the enantiopure R-(-)-
isomer, armodafinil (Nuvigil), was approved in 2007 for the same indications. There is 
now consistent evidence that modafinil can improve prefrontal-dependent cognitive 
functions of healthy individuals in processes requiring cognitive control. Related neural 
circuitry and the remediation of cognitive dysfunction may form a basis of future clinical 
efficacy of this agent across many neuropsychiatric disorders (Minzenberg et al 2008). 
 
With discovery of this novel pharmaceutical class, research into analogues of the 
chemical structure is current and widespread- in aims for clinical development of a more 
efficacious compound than the original FDA approved drug. Comparative 
pharmacological studies with modafinil, its enantiomers, and structural analogues have 
appeared in literature. Screenings of receptors and transporters in an attempt to elucidate 
its pharmacology frequently has centered on the indirect involvement of monoamine 
transporters: dopamine transporter (DAT), norepinephrine transporter (NET), serotonin 
transporter (SERT). With these suggested pharmacological targets, research into novel 
ligands pertaining to their potency and selectivity profiles has been quantified through 
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Cephalon’s numerous publications “Wake-promoting agents: Search for the Next 
Generation Modafinil” (Chatterjee et al. 2012) demonstrate they look to be streamlining 
the molecule as a lead compound. Selecting candidate compounds based on waking time 
in physiological assays and highest DAT selectivity indicates Chatterjee et al. are 
screening analogues for a more stimulating compound. Cephalon Inc. has since disclosed 
numerous publications of their work on lead modifications, creating biphenylic, tricyclic 
and aryl-heteroaryl modafinil derivatives. For the purpose of this paper, we will focus on 
a biphenyl derived wake-promoting agent. Maintaining the sulfinylacetamide moiety 
intact, Chatterjee et al., a Cephalon research group, rearranged the two phenyl rings of the 
parent molecule, generating a series of ortho-, meta- and para-oriented biphenyls. Ortho-
substitution of aromatic rings in the parent compound displayed equal potency in wake-
promoting activity of rats, whereas explored meta- and ortho-orientations yielded no 
additional benefit. P-halogen substitution increased activity in the order H < F < Br < Cl. 
 
Chatterjee’s publication “Search for the Next Generation Modafinil” part I selected a 
fairly promising successor to modafinil for further investigation in part II.  
Referred to as ‘Compound 2,’ 2-{[2-(4-chlorophenyl)phenyl]methylsulfinyl}acetamide 
(figure 1) was assayed for transporter binding/uptake inhibition in rats (table 1). Racemic 
‘Compound 2’ or (±)-2 displayed selectivity for DAT and NET, whereas SERT binding 
was unaltered- remaining negligible. Micromolar binding affinities of (±)-2 improved 
six-fold at both DAT and NET relative to (±)-modafinil. Results describe ‘Compound 2’ 
as a pure eugeroic with a long half life- in the modafinil range.  
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Table 1-  
Transporter binding/uptake inhibition data for compounds (±)-1, (±)-2, (-)-2, and (+)-2 
Assay (rat) 100mg/kg Modafinil (±)-2 (-)-2 (+)-2 
DAT binding (IC50 µM) 3.70 0.6 0.40 4.20 
NET binding (IC50 µM or % inhibition) N/A N/A 16%@10µM 12%@10µM 
SERT binding (IC50 µM or % inhibition) N/A N/A 3%@10µM 4%@10µM 
CYP2C19 (IC50 µM or % inhibition) 11 19 174 112 
CYP3A4 (IC50 µM or % inhibition) <10%@10 µM <10%@10 µM 139 159 
CYP2D6 (IC50 µM or % inhibition) <10%@10 µM <10%@10 µM 177 151 
Rat waking time (min) over 4hr *117± 13 *176± 4 238.5± 0.8 227.1± 7.8 
* Data represents waking time over 3hr 
 
Scheme 1-  
Synthesis Route “Compound 2” as executed by Chatterjee et al.  
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The application of halogen substituents exist in many pharmaceuticals, however only 
recently has stabilizing interactions of halogen bonding been explored. (Xu et al. 2012). 
In a database survey, Xu et al. validate the contributions of halogen bonds to enhance 
drug-target binding affinity and selectivity. Halogenation has potential to improve ligand 
bioactivity in pharmacokinetics and pharmacodynamics (Xu et al. 2014). Wilcken et al. 
further revealed that, granted favorable orientation, a ligand’s ability to form a halogen 
bond interaction at receptor target may result in an increase of affinity. Accordingly, 
fluoro- bromo- and chloro- substituted modafinil analogues have been reported as 
stimulating (De Risi et al. 2008). Previous studies lacking any binding assay have been 
substantiated by Cao et al. Synthesis of several aryl halide analogues elucidated para-
halogen substitution at the diphenylmethyl moiety of racemic modafinil improves 





MAT Binding Data for Sulfinylacetamide Analogues 
(Cao et al. 2014) 
 
 
Substitution X, Y Ki [SE interval or ± SEM] nM 
DAT SERT NET 
(±)-1 modafinil H 2520 ± 204 ND/IA ND/IA 
S-(+)-1 H 7640 ± 395 ND/IA ND/IA 
R-(-)-1 H 3260 ± 195 ND/IA ND/IA 
5b 4,4’-di-F 2190 ± 139 ND ND 
5c 4,4’-di-Cl 919 ± 52.8 39000 ± 2410 ND 
5d 4,4’-di-Br 600 ± 47.3 10600 ± 1110 ND 
3b 3,3’-di-F 5930 [4990-7060] IA IA 
3c 3,3’-di-Cl 881 [763-1020] IA IA 
3d H, 3-Br 550 [542-557] IA IA 
IA = inactive, defined as <50% inhibition at 100 µM. ND = no displacement up to concentration 10 µM 
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China Pharmaceutical University research group, Zhu et al., synthesized a series of  
2-[(diphenylmethyl)thio]acetamide and 2-[(diphenylmethyl)sulfinyl]acetamide 
(Modafinil) analogues with moiety alterations of the primary amide to various secondary 
amides. In a biological-activity assay, Zhu et al. measured "Inhibition rate of independent 
activity (after administration)", and after 3hr the control mice scored -50.4 and the 
modafinil mice scored 69.1 (Table 3). One of the analogues, “Compound 6h,” with a 3-
chloroaniline attached at terminal amide beat modafinil at the 3-hour mark, scoring 81.5. 
Zhu's ‘Compound 6h’ looks to be fairly long half-lived, at least longer than modafinil, 






Figure 3- Zhu 6h 
      
2-[(diphenylmethyl)sulfinyl]-N-(3-chlorophenyl)acetamide 
 
The 3-chloroaniline moiety, as a substituted amide, was only synthesized onto a           
2-[(diphenylmethyl)thio]N-(3-chlorophenyl)acetamide. Zhu et al. did not substitute 
modafinil’s original sulfinylacetamide appendage with this 3-chloroaniline group. Work 
by Zhu et al. support a stimulatory influence of the sulfoxide through biological assay of 
novel modafinil derivatives. Identical moieties of Pyrrolidine and Piperdine were studied 
on both sulfinyl- and thio-acetamides, substituted as R-group to the terminal amide. 
Secondary amide substitution of Pyrrolidine and Piperdine are ‘6c’ and ‘6d’ respectively 
on a sulfinylacetamide, whereas Pyrrolidine and Piperdine are ‘6j’ and ‘6i’ coupled to a 
thioacetamide appendage (see table 3). 
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Behavioral responses indicate a marked increase in activity with each moiety attached to 
a sulfinylacetamide. Therefore, 2-[(diphenylmethyl)sulfinyl]-N-(3-chlorophenyl)-
acetamide analogue would likely elicit an even stronger biological response than 
‘compound 6h.’  
 
Table 3- Effect of target compounds on independent activities of mice  
Inhibition Rate of Independent Activity  = x100% 
   (n = 8 mice) 
 
Compound Inhibition Rate of Independent Activity (%) 
30min 1 hr 2 hr 3 hr 
Control -16.5 -33.2 -45.8 -50.4 
Modafinil 29.9 48.2 58.1 69.1 
6h 30.6 68.9 69.4 81.5 
6c 5.2 7.8 21.4 24.3 
6d -27.7 -31.6 -21.1 -27.8 
6i -18.8 -11.4 -39.3 -50.4 
6j -22.2 -36.4 -38.7 -54.2 
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The increased stimulatory effect elicited by addition of S=O moiety is made intelligible 
through enhanced affinity for the DAT relative its thioether isostere. Cao et al. evaluated 
binding affinities of several novel analogues at the monoamine transporters (MATs) in rat 
brain membranes. Utilizing bioisosteric replacement of the sulfoxide with thioether, Cao 
et al. compared SARs of the sulfinylacetamide appendage to that of thioacetamide 
derivatives. Reducing the S=O to sulfur decreased DAT affinity five-fold, while binding 









MAT Binding Data for Sulfinylacetamide Analogues 
 Ki nM ± SEM 
DAT SERT NET 
4c 2230 ± 166 12700 ± 520 52100 ± 5510 
5c 919 ± 52.8 39000 ± 2410 ND 
 Synthetic route (Cao et al. 2014) 
 
 
The S=O moiety was found to be optimal for DAT binding; further, this sulfoxide group 
significantly decreases binding at SERT relative its isostere, sulfur. Knowing the 
sulfoxide plays a key role in stimulating effects of modafinil and its analogues, its 
presence remains in this work’s choice compound. 
4c	  5c	  
	   10	  
Compound 2 and Zhu 6h outlined in this paper, independently exhibit more selectively 
stimulatory pharmacological profiles than (±)-1 modafinil. Although potency does not 
always translate to efficacy, a successful modafinil analogue needs to be more selective, 
with less ancillary side effects. Seeing that the surface has barely been scratched on 2-
substituted biphenyl modafinil derivatives, we hybridized Chatterjee et al. ‘Compound 2’ 





Theoretical synthesis scheme based on literature procedure: 
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Theoretical synthetic procedure: 
I—   
2-iodobenzyl alcohol (0.64mol, 150g) is coupled with 4-chlorophenyl boronic acid 
(0.64mol, 100g) in a vessel containing 2 equivalents of 2M sodium carbonate, solvent 
EtOH-toluene and the driving palladium catalyst Pd(PPh3)4. Raise temperature to 80 °C 
for 3hr to yield 2-[2-(4-chlorophenyl)phenyl]methanol A.  
We assume 80% yield (111g, 51mol) A  [Chatterjee et al. report 80% yield] 
 
II—   
To form the isothiouronium salt 2-[2-(4 chlorophenyl)phenyl]isothiouronium B, combine 
A (111g, 0.71mol) and thiourea (0.85mol, 65g) in 0.5L vessel with 325mL water. Heat 
mixture to 60 °C to obtain emulsion, then add 2.3 equivalents 48% HBr (130g, 1.6mol) 
gradually over 0.5 hr. Achieve reflux for .5 hr, then slowly cool to 25 °C. Filter product 
(crystals) and wash with water.  
We assume 90% yield (176g, .64mol) B [achieved by similar reactions outlined in US 
Patent 6,649,796 and Chatterjee et al.] 
 
III—  
Hydrolysis of thiouronium salt to 2-[2-(4–Chlorophenyl)phenyl]methylthioacetamide C:  
To a vessel containing B (176g), water (600ml), add 2 equivalents 30% NaOH 100ml, 1.7 
mol), heat reaction mixture to 80 °C and stir for 1 hr until a homogenous solution is 
achieved. Cool mildly and add chloroacetic acid (81g, 0.84 mol) in portions. Then reflux 
the suspension for 2 hr. Filter and wash with hot water. 
We assume a 90% yeild (169g, 0.57mol) C [US Patent 6,649,796]. 
 
IV—  
Stir mixture of C (169g, 0.57mol), EDC (1-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide) (89g, 0.57mol) and HOBt (hydroxybenzotriazole) (77g, 0.57mol) at 25 °C 
for .5 hr in acetonitrile solvent to activate acid. Next, add 3-chloroanaline (72.7g, 
0.57mol) and stir for 24hours. Recrystallize with ethyl acetate to yield 158g, 0.39mol D 
2-{[2-(4–Chlorophenyl)phenyl]methylthio}-N-(3-chlorophenyl)acetamide  
[Lari et al. accomplish a 68% yield via this procedure]. 
 
V—  
Oxidation of sulfur to sulfoxide. Dissolve D (150g, 0.38mol) in glacial acetic acid 
(610ml), then stir in 30% H2O2 (57mL) dropwise. Keep reaction stirring below 25 °C for 
4 hrs; promptly wash with cold water. Note: oxidation reaction via H2O2 must remain 
cool and workup done soon thereafter, otherwise risk forming sulfone. Recrystallization 
via ethanol:water (3:1) [80% yield by both Mu et al. and Lari et al.] 129g, 0.3mol product 
2-{[2-(4-chlorophenyl)phenyl]methylsulfinyl}-N-(3-chlorophenyl)acetamide. 
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List of reagents utilized in synthetic route:
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Hypothesized Mechanism of Action: 
  
Despite copious research publications, modafinil’s mechanism of action (MoA) as-yet 
remains to be elucidated. Neurochemical substrates of modafinil currently uncovered 
include agonism at dopamine (D2) and alpha-1-adrenergic receptors. Directly enhancing 
conductance across neuronal membranes, modafinil, amplifies presynaptic Na/Ca influx; 
resultant widespread depolarization of cortical interneurons could theoretically allow 
transient, voltage-dependent inhibition of monoamine reuptake- resembling action of 
conventional stimulants, minus the stereotypy, euphoria, and locomotor effects. 
 
Modafinil’s direct dopaminergic inhibition is related to D2-receptor-activation, an action 
that remains independent of the adrenergic system. Investigating midbrain dopaminergic 
neurons in rat brain slices, Lin et al 2007, describe a novel agonistic action of modafinil 
on D2-like-receptors. Sulpride (D2 pre-synaptic antagonist), but not prazosin (α1-AR 
antagonist) abolished modafinil-induced inhibition of dopaminergic neurons (Lin et al 
2007). Furthermore, pre-treatment with the voltage-gated sodium channel blocker 
tetrodotoxin did not prevent reduction in firing rate in DA neurons, providing good 
evidence that this result was a consequence of a direct postsynaptic effect. Activation of 
D2-like receptors can be further attributed to the influence by which modafinil 
ameliorates serotonin (5-HT) exocytosis and attenuates gamma-aminobutyric acid 
(GABA) release. The excitatory function of D2 receptors increases serotonin release of 
dorsal raphe 5-HT neurons (Haj-Dahmane, 2007) and inhibits GABAergic tone in the 
striatum (Ferraro et al., 1998).  
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Next, we present a hypothesized MoA linking alpha-1-adrenergic receptor agonism to a 
theory of enhanced electrotonic coupling. In contrast to chemical synapses, groups of 
cortical neurons are electrically coupled, such that changes in membrane potential are 
rapidly communicated to adjacent cells. Gap junctions permit diffusion of current across 
linked cells, allowing more rapid membrane polarization. This enhanced conductance 
across membranes lowers electrical resistance of the neuronal network. Decreased 
electrical resistance of the network relative to an individual cell requires a larger current 
to reach a voltage sufficient to trigger action potentials (Siegel 2008). Knowing that tonic 
response of a nerve ending is typified by slow, continuous action over duration of 
stimulus, once an action potential does arise in cells connected by gap junctions, the 
entire populations tend to fire in a synchronized manner. Thus, enhanced electrotonic 
coupling results in lower tonic activity of the coupled cells while increasing rhythmicity 
of neuronal communication.  
 
Beck et al. present data suggesting that modafinil acts by ‘opening’ gap junctions 
between neurons. This means increased permeability of membranes allows direct 
connection of the cytoplasm of two cells, hence ameliorating bidirectional diffusion of 
ion currents. Further, through measurements of the arousal-specific P13 evoked potential, 
Beck et al. suggest a direct link between electrotonic coupling and wakefulness as one 
mechanism by which modafinil increases arousal. Upon administration of modafinil to 
freely moving rats, amplitudes of P13 markedly increased; however, with pretreatment of 
the gap junction blocker, mefloquine, this effect was abolished (Beck et al. 2008). 
Interestingly, Urbano et al. independently demonstrated modafinil’s mechanistic 
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mediation of gap junctions to be non-compete with mefloquine. After implementing 
mefloquine, irreversibly blocking gap junction protein (connexin) permeability, modafinil 
restored electrotonic coupling within 30 minutes of administration.  
 
Urbano et al. determined that modafinil increases electrical coupling between cortical 
interneurons implemented through a Ca2+/calmodulin protein kinase II-dependent step. In 
vitro treatment of KN-93, a calcium/calmodulin dependent protein kinase II (CaMKII) 
inhibitor, abolished modafinil’s enhancement of electrotonic coupling (Urbano 2007). 
Acting from intracellular side, CaMKII is shown to potentiate channel activity (Dietrich 
2007). This enhanced ionic current through pours that link adjacent cells amplifies Na/Ca 
influx, leading to widespread depolarization. Therefore, modafinil could modulate 
exocytosis of gap junctions via a Ca2+/calmodulin dependent enzyme. 
 
Interestingly, this theoretical reuptake-inhibition/release mechanism- that does not 
involve specific binding sites at the transporter molecules- would be similar to that of 
hyperforin, a major constituent chemical in St John’s Wort. Broad-spectrum reuptake 
inhibition of monoamines via presynaptic TRPC6 activation induces influx of Na+, Ca2+ 
and effectively elevates intracellular concentrations (Leuner et al 2007; Zanoli 2004). 
Widespread depolarization of cortical interneurons, consistent with hypothesized 
mechanisms of modafinil and hyperforin, throws into stark relief a transient, voltage-
dependent inhibition of monoamine re-uptake.  
 
Transient receptor potential channel, TRPC6, is a non-selective cation channel, which as 
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demonstrated by Dietrich et al, exhibits nearly coequal electrophysiological properties to 
adrenergic non-specific cation channels, α1-AR-NSCC. Expressed in the brain and 
smooth muscle tissue, Ca2+ permeable TRPC6 currents are activated by α1-AR 
stimulation (Dietrich et al 2007). In the manner that Urbano et al. displayed CaMKII 
inhibition to abolish modafinil’s enhancement of electrotonic coupling, inhibition of 
Ca2+/Calmodulin-dependent protein kinase II was further extended to an inhibitory effect 
on TRPC6. Boulay et al. showed the calmodulin inhibitor, calmidazolium, abolished 
calcium influx into TRPC6 cells. Action of calmidazolium inhibits calmodulin-dependent 
phosphodiesterase, which alludes to a hypothesis by Shi et al.- TRPC6 activation 
involves phosphorylation by CaMKII. 
 
Modafinil’s capacity to modulate gap junction through a Ca2+/calmodulin dependent 
enzyme can be further extrapolated as a downstream effect of TRPC6 channel activation. 
Subsequent research by Dietrich et al. pertaining to potentiating action of Ca2+ on TRPC6 
and α1-AR–NSCC strongly suggests TRPC6 protein may be an essential molecular 
component of α1-adrenoceptors. Stone et al. observed marked attenuation of behavioral 
activation caused by modafinil from either pharmacological blockade or genetic ablation 
of alpha1-adrenoceptors (α1-AR). Therefore, central a1-adrenergic tone being 
indispensable of the manifestation of the stimulant or waking effects of modafinil relates 
theory of enhanced conductance to noradrenergic transmission. 
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